At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Bermekimab Monoclonal Antibody 400 mgdrug
Likely dose
Bermekimab Monoclonal Antibody 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Bermekimab Monoclonal Antibody 400 mg for Hidradenitis Suppurativa. Completed, enrolled 42 participants across 1 site.
Detailed Summary
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJun 2018
Primary CompletionJan 2019
TodayJul 2026
First PostedApr 30, 2018
Enrollment StartJun 20, 2018
Primary CompletionJan 14, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.2 years ago
Interventions
Bermekimab Monoclonal Antibody 400 mgdrug
subcutaneous injection